Verastem restructures $75M Oberland facility, adds up to $75M in revenue-linked notes, and posts Q2 update

summarizeSummary

Verastem amended its Oberland Capital facility to add up to $75 million in revenue-linked notes, with the first $50 million closing this month. The company also reported Q2 product revenue of $25.1 million and updated its pipeline progress.

check_boxKey Events · Financing and Capital Events · VSTM

• Revenue Notes Replace Prior Tranches

  Amendment No. 3 replaces the previous conditional second and third tranches with a new series of Revenue Notes totaling up to $75 million. The first $50 million tranche will be issued on August 28, 2026, with an optional $25 million available until May 15, 2027, contingent on quarterly net sales of avutometinib and defactinib reaching at least $40 million.

• Revenue-Linked Repayment Structure

  The Revenue Notes carry a 4.50% revenue payment percentage on net sales of the combination product, decreasing to 1.75% if total revenue payments equal 100% of the funded amount by December 31, 2031. If not, a one-time make-whole payment equal to the shortfall is due. The notes mature June 30, 2033, with redemption premiums ranging from 135% to 185% of the funded amount.

• Initial Notes Royalty Fixed at 1.00%

  The amendment fixes the Revenue Participation Percentage on the existing $75 million Initial Notes at 1.00%, removing the prior provision that would have increased the rate to 2.00% if additional notes were issued.

• Q2 2026 Revenue and Pipeline Update

  The corporate presentation posted as Exhibit 99.1 reports Q2 2026 net product revenue of $25.1 million for AVMAPKI FAKZYNJA CO-PACK, up from $18.7 million in Q1 2026. It also highlights progress on VS-7375, a KRAS G12D inhibitor, with three registration-directed Phase 2 trials now enrolling in pancreatic, lung, and colorectal cancers.

auto_awesomeAnalysis · VSTM · Life Sciences

Verastem amended its Oberland Capital credit facility, replacing two conditional tranches with a new series of Revenue Notes that provide up to $75 million in additional capital. The first $50 million tranche closes August 28, 2026, with an optional $25 million available if quarterly sales of its approved combination therapy hit $40 million. The Revenue Notes carry a 4.50% royalty on product sales, stepping down to 1.75% once the funded amount is repaid via royalties by end of 2031. This structure reduces near-term cash interest costs compared to the prior fixed-rate notes but creates a long-term revenue obligation. The amendment also fixes the royalty on the existing $75 million Initial Notes at 1.00%, removing a prior escalator. Separately, the company posted an investor deck showing Q2 net product revenue of $25.1 million, up 34% sequentially, and highlighted progress on its KRAS G12D inhibitor VS-7375, with three registration-directed Phase 2 trials now enrolling. The financing extends cash runway into the second half of 2027, but the revenue-linked structure means a portion of future sales will flow to Oberland before equity holders.